{"id":"W2113562909","doi":"10.1177/1758834009352498","title":"Review: Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions","year":2009,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; BC Cancer Agency","funders":"","keywords":"Temsirolimus; Pazopanib; Medicine; Axitinib; Sorafenib; Sunitinib; Bevacizumab; Everolimus; Renal cell carcinoma; Targeted therapy; Oncology; PI3K/AKT/mTOR pathway; Adjuvant; Clinical trial; Vascular endothelial growth factor; Adjuvant therapy; Internal medicine; Pharmacology; Discovery and development of mTOR inhibitors; Cancer; VEGF receptors; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001136237,0.00104846,0.002239981,0.001632774,0.0003914931,0.001418323,0.001556379,0.0022055,0.009713172],"category_scores_gemma":[0.00224303,0.0002122513,0.0006933933,0.002358574,0.0006979041,0.002578041,0.0005168979,0.002171854,0.006410961],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008260026,"about_ca_system_score_gemma":0.001316065,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001186937,"about_ca_topic_score_gemma":0.002420551,"domain_scores_codex":[0.9995271,0.0001582408,0.00007507022,0.00005312884,0.0001550902,0.00003135071],"domain_scores_gemma":[0.9986234,0.0006427426,0.0001422324,0.00002649921,0.0004236998,0.0001415059],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002079848,0.00008383558,0.0002019778,0.0137644,0.0001000708,0.0003801574,0.00003152884,0.0003393494,0.0005317511,0.001182114,0.3207904,0.6623864],"study_design_scores_gemma":[0.00008025354,0.0001352202,0.0008439049,0.005158461,0.0001459192,0.002202554,0.00005872751,0.0001070208,0.0001183729,0.00137142,0.98976,0.00001820456],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00009525067,0.991996,0.0002023158,0.003047745,0.003185073,0.0000173705,0.00002971118,0.00001395883,0.001412538],"genre_scores_gemma":[0.0005624783,0.9925693,0.0002986027,0.002260898,0.002893453,0.00002063453,0.00004949514,0.000003924998,0.001341298],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.009713172,"threshold_uncertainty_score":0.03249383,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03495072061428077,"score_gpt":0.3814300607698013,"score_spread":0.3464793401555206,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}